维得利珠单抗与抗肿瘤坏死因子药物在生物制剂初治溃疡性结肠炎患者中的真实世界有效性:前瞻性观察性VEDOIBD研究的两年倾向评分校正分析
基于德国45个炎症性肠病中心2017至2020年前瞻性纳入的314例生物制剂初治溃疡性结肠炎患者,比较维得利珠单抗与抗肿瘤坏死因子药物的有效性。诱导期临床缓解率两组相似(23% vs 30.4%,p=0.204),但治疗两年后维得利珠单抗组缓解率显著更高(43.2% vs 25.8%,p<0.011),且换药比例更低(29% vs 54%)。
要点
- 诱导期临床缓解率维得利珠单抗组23% vs 抗肿瘤坏死因子组30.4%,差异无统计学意义(p=0.204)。
- 治疗两年后临床缓解率维得利珠单抗组43.2% vs 抗肿瘤坏死因子组25.8%,差异有统计学意义(p<0.011)。
- 维得利珠单抗组29%换用其他生物制剂,抗肿瘤坏死因子组54%换药。
核心结论
- 治疗两年后,维得利珠单抗相比抗肿瘤坏死因子药物在生物制剂初治溃疡性结肠炎患者中带来更高的缓解率。
研究设计与样本
- 基于VEDOIBD登记研究的前瞻性观察性真实世界证据研究。
- 2017年至2020年在德国45个炎症性肠病中心纳入512例开始维得利珠单抗或抗肿瘤坏死因子治疗的溃疡性结肠炎患者。
- 排除生物制剂经治患者及缺失部分Mayo(pMayo)结局者后,最终样本314例(维得利珠单抗182例,抗肿瘤坏死因子132例)。
- 主要结局为采用pMayo评分测量的临床缓解,任何换用不同生物制剂均视为结局失败(改良意向性治疗分析)。
- 采用倾向评分校正,以逆概率治疗加权校正混杂。
主要发现
- 诱导治疗期间,维得利珠单抗组与抗肿瘤坏死因子组临床缓解率分别为23%与30.4%(p=0.204)。
- 治疗两年后,维得利珠单抗组临床缓解率43.2% vs 抗肿瘤坏死因子组25.8%(p<0.011)。
- 维得利珠单抗组29%换用其他生物制剂,抗肿瘤坏死因子组54%换药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This observational real-world evidence (RWE) study is based on prospectively collected data from the VEDOIBD registry study. AIM: To compare the effectiveness of vedolizumab and anti-TNF agents in biologic-naïve patients with ulcerative colitis (UC) at the end of induction and during maintenance treatment. METHODS: Between 2017 and 2020, we enrolled 512 patients with UC starting therapy with vedolizumab or an anti-TNF agent in 45 IBD centres across Germany. We excluded biologic-experienced patients and those with missing partial Mayo (pMayo) outcomes; this resulted in a final sample of 314 (182 on vedolizumab and 132 on an anti-TNF agent). The primary outcome was clinical remission measured using pMayo score; any switch to a different biologic agent was considered an outcome failure (modified ITT analysis). We used propensity score adjustment with inverse probability of treatment weighting to correct for confounding. RESULTS: During induction therapy, clinical remission was relatively low and similar in vedolizumab- and anti-TNF-treated patients (23% vs. 30.4%, p = 0.204). However, clinical remission rates after two years were significantly higher for vedolizumab-treated patients than those treated with an anti-TNF agent (43.2% vs. 25.8%, p < 0.011). Among patients treated with vedolzumab, 29% switched to other biologics, versus 54% who had received an anti-TNF agent. CONCLUSION: After two years of treatment, vedolizumab resulted in higher remission rates than anti-TNF agents.
引用
- Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, et al. Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naïve patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDOIBD -study. Aliment Pharmacol Ther. 2023. PMID: 37322825. doi:10.1111/apt.17616
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。